View Financial HealthPasithea Therapeutics 배당 및 자사주 매입배당 기준 점검 0/6Pasithea Therapeutics 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-305.0%자사주 매입 수익률총 주주 수익률-305.0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트Pasithea Therapeutics Corp. (NasdaqCM:KTTA) announces an Equity Buyback for 5,700,000 shares, for $4 million.Jul 23+ 1 more update모든 업데이트 보기Recent updatesPasithea Therapeutics Corp Announces Grant of Rare Pediatric Disease Designation by FDA to Pas-004 for Treatment of Neurofibromatosis Type 1Apr 21Pasithea Therapeutics Corp Announces Grant of Fast Track Designation by Fda to Pas-004 for Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Causing Significant MorbidityApr 01Pasithea Therapeutics Corp. Receives Notice of Non-Compliance with Nasdaq Minimum Bid Price Listing RuleFeb 21Pasithea Therapeutics Provides Outlook on Pas-004 Clinical Programs and Data Release TimelinesJan 13Pasithea Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $59.934847 million.Dec 02Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering.Nov 27Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) DataNov 25Pasithea Therapeutics Corp. Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 PatientsNov 22+ 1 more updateNew minor risk - Share price stability Nov 20Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $10 million.Nov 19Pasithea Therapeutics Corp. Announces Activation of Clinical Trial Site At University of Alabama At Birmingham for Ongoing Phase 1/1B Trial of Pas-004 in Adult Nf1 PatientsNov 06Pasithea Therapeutics Corp. Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 PatientsSep 16Pasithea Therapeutics Corp. Announces Enrollment of Cohort 2 Following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsSep 08New major risk - Financial position Aug 15Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsJul 31Pasithea Therapeutics Corp., Annual General Meeting, Sep 03, 2025Jul 16Pasithea Therapeutics Receives Nasdaq Non-Compliance Notice Regarding Minimum Bid Price RequirementJun 29Pasithea Therapeutics Appoints James Lee to Scientific Advisory BoardJun 11Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 At the ASCO Annual Meeting 2025Jun 02Pasithea Therapeutics Announces Preclinical Data That Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market DiseasesMay 20Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial SiteMay 15Pasithea Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $4.999522 million.May 09Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004May 08Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering.May 01Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer PatientsApr 30Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual MeetingApr 24Pasithea Therapeutics Corp. Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerApr 13New major risk - Shareholder dilution Mar 26New major risk - Financial position Mar 25New minor risk - Share price stability Feb 05Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation from Its Ongoing Phase 1 Clinical Trial of Pas-004 in Advanced CancerFeb 05Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $2.076 million.Nov 27Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerNov 20New major risk - Financial position Nov 15Pasithea Therapeutics Corp. announced that it has received $5.000003 million in fundingOct 01Pasithea Therapeutics Corp. announced that it expects to receive $5.000003 million in fundingSep 27Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory BoardSep 03New minor risk - Share price stability Jul 30Pasithea Therapeutics Corp. Announces Completion of Enrollment and Initial Dosing of Cohort 2 Following Positive Safety Review Committee Recommendation for PAS-004 in Ongoing Phase 1 Clinical TrialJun 15Pasithea Therapeutics Corp., Annual General Meeting, Jun 26, 2024May 17Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated CancersApr 25Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004Feb 14Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionJan 10Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer PatientsJan 02New major risk - Financial position Nov 20Pasithea Therapeutics Corp. Selects PAS-003 Lead Development CandidateNov 10Pasithea Therapeutics Corp., Annual General Meeting, Nov 29, 2023Oct 27High number of new and inexperienced directors Oct 20Pasithea Therapeutics Corp. Publishes Study in Proceedings of the National Academy of Sciences Related to its PAS-003 Drug Discovery ProgramAug 02Pasithea Therapeutics Corp. (NasdaqCM:KTTA) announces an Equity Buyback for 5,700,000 shares, for $4 million.Jul 23+ 1 more updateNew major risk - Share price stability Jul 21Lucy Scientific Discovery Inc. (NasdaqCM:LSDI) made a proposal to acquire Pasithea Therapeutics Corp. (NasdaqCM:KTTA) for $22.2 million.Jun 07Pasithea Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Bid Price RequirementJan 26Concord IP2 Recommends Stockholders to Vote for Boardroom Change at Pasithea TherapeuticsDec 08Price target decreased to US$2.30 Nov 16Less than half of directors are independent Nov 16Concord IP2 Ltd Files a Lawsuit Against the Directors of Pasithea Therapeutics Corp Nov 02Camac Partners Comments on Pasithea Therapeutics’ Acquisition of AlloMek TherapeuticsOct 14Pasithea Therapeutics Corp. (NasdaqCM:KTTA) acquired AlloMek Therapeutics, LLC from Integral Biosciences Private Limited, Innovation Pathways LLC, Shakti BioResearch LLC and others for $11.3 million.Oct 13+ 1 more updateCamac Partners LLC Sends a Letter to Pasithea Therapeutics CorpSep 30Less than half of directors are independent Sep 23Pasithea Therapeutics Corp. Appoints Alfred J. Novak to Its Board of DirectorsSep 21Pasithea Therapeutics Corp. Appoints Dr. Merit Cudkowicz to its Scientific Advisory BoardSep 16Camac Partners Provides Information to Shareholders of Pasithea TherapeuticsSep 09+ 1 more updateCamac Partners Urges Stockholders of Pasithea Therapeutics to Vote to Call Special MeetingAug 26Pasithea Therapeutics Corp. Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple SclerosisAug 12Concord Investment Partners Ltd Urges Stockholders of Pasithea Therapeutics Corp to Call Special MeetingAug 06Concord IP2 Ltd Nominates Candidates to the Board of Pasithea Therapeutics CorpJul 29We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn RateJul 21Concord IP2 Ltd Files Solicitation Statement to Call a Special Meeting of Stockholders of Pasithea Therapeutics CorpJul 02Concord IP2 Ltd Provides Information to Shareholders of Pasithea Therapeutics CorpJun 28Concord IP2 Ltd Sends a Letter to Pasithea Therapeutics CorpJun 17Stanley Gloss, the Chief Financial Officer of Pasithea Therapeutics Corp., Passes AwayJun 11Concord IP2 Ltd Sends a Letter to Pasithea Therapeutics CorpJun 02Pasithea Therapeutics Corp., Annual General Meeting, Jun 23, 2022May 14Less than half of directors are independent Apr 27Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn SituationApr 06Pasithea Therapeutics Appoints Daniel Weinberger to Its Scientific Advisory BoardFeb 10Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple SclerosisFeb 04Pasithea Therapeutics Corp. announced that it has received $30.38 million in fundingNov 30Pasithea Therapeutics Corp. announced that it expects to receive $30.38 million in fundingNov 26Pasithea Therapeutics Adds Esketamine Nasal Spray to Its Clinic Offerings in the U.KNov 24지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 KTTA 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: KTTA 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Pasithea Therapeutics 배당 수익률 vs 시장KTTA의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (KTTA)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.6%분석가 예측 (KTTA) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 KTTA 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 KTTA 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 KTTA 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: KTTA 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/03 05:23종가2026/05/01 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pasithea Therapeutics Corp.는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Sara NikH.C. Wainwright & Co.
Pasithea Therapeutics Corp. (NasdaqCM:KTTA) announces an Equity Buyback for 5,700,000 shares, for $4 million.Jul 23+ 1 more update
Pasithea Therapeutics Corp Announces Grant of Rare Pediatric Disease Designation by FDA to Pas-004 for Treatment of Neurofibromatosis Type 1Apr 21
Pasithea Therapeutics Corp Announces Grant of Fast Track Designation by Fda to Pas-004 for Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Causing Significant MorbidityApr 01
Pasithea Therapeutics Corp. Receives Notice of Non-Compliance with Nasdaq Minimum Bid Price Listing RuleFeb 21
Pasithea Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $59.934847 million.Dec 02
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) DataNov 25
Pasithea Therapeutics Corp. Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 PatientsNov 22+ 1 more update
Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $10 million.Nov 19
Pasithea Therapeutics Corp. Announces Activation of Clinical Trial Site At University of Alabama At Birmingham for Ongoing Phase 1/1B Trial of Pas-004 in Adult Nf1 PatientsNov 06
Pasithea Therapeutics Corp. Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 PatientsSep 16
Pasithea Therapeutics Corp. Announces Enrollment of Cohort 2 Following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsSep 08
Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsJul 31
Pasithea Therapeutics Receives Nasdaq Non-Compliance Notice Regarding Minimum Bid Price RequirementJun 29
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 At the ASCO Annual Meeting 2025Jun 02
Pasithea Therapeutics Announces Preclinical Data That Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market DiseasesMay 20
Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial SiteMay 15
Pasithea Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $4.999522 million.May 09
Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004May 08
Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer PatientsApr 30
Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual MeetingApr 24
Pasithea Therapeutics Corp. Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerApr 13
Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation from Its Ongoing Phase 1 Clinical Trial of Pas-004 in Advanced CancerFeb 05
Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $2.076 million.Nov 27
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerNov 20
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory BoardSep 03
Pasithea Therapeutics Corp. Announces Completion of Enrollment and Initial Dosing of Cohort 2 Following Positive Safety Review Committee Recommendation for PAS-004 in Ongoing Phase 1 Clinical TrialJun 15
Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated CancersApr 25
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004Feb 14
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionJan 10
Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer PatientsJan 02
Pasithea Therapeutics Corp. Publishes Study in Proceedings of the National Academy of Sciences Related to its PAS-003 Drug Discovery ProgramAug 02
Pasithea Therapeutics Corp. (NasdaqCM:KTTA) announces an Equity Buyback for 5,700,000 shares, for $4 million.Jul 23+ 1 more update
Lucy Scientific Discovery Inc. (NasdaqCM:LSDI) made a proposal to acquire Pasithea Therapeutics Corp. (NasdaqCM:KTTA) for $22.2 million.Jun 07
Pasithea Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Bid Price RequirementJan 26
Pasithea Therapeutics Corp. (NasdaqCM:KTTA) acquired AlloMek Therapeutics, LLC from Integral Biosciences Private Limited, Innovation Pathways LLC, Shakti BioResearch LLC and others for $11.3 million.Oct 13+ 1 more update
Pasithea Therapeutics Corp. Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple SclerosisAug 12
Concord Investment Partners Ltd Urges Stockholders of Pasithea Therapeutics Corp to Call Special MeetingAug 06
Concord IP2 Ltd Files Solicitation Statement to Call a Special Meeting of Stockholders of Pasithea Therapeutics CorpJul 02
Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn SituationApr 06
Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple SclerosisFeb 04
